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a b s t r a c t
Elevated circulating levels of acute phase proteins (APP) are associated with inﬂammation and inﬂam-
matory disorders such as cardiovascular disease. APP are mainly synthesised by hepatocytes and their
transcription is inducedbypro-inﬂammatory cytokines such as interleukin-1 (IL-1). Themolecularmech-
anismsunderlying the IL-1-induced expression of key transcription factors implicated in the regulation of
APParepoorlyunderstood.Wehave investigated this aspect using theCCAAT/enhancer bindingprotein-
(C/EBP) as a model gene. IL-1 induced the expression of C/EBP mRNA and protein in the human hep-
atoma Hep3B cell line, a widely employed model system for studies on cytokine signalling in relation to
the expression of APP. The IL-1-mediated induction of C/EBP expressionwas attenuated in the presence
of pharmacological inhibitors against c-Jun N-terminal kinase (JNK) (curcumin and SP600125), caseinCAAT/enhancer binding proteins
epatocytes
nterleukin-1
ell signalling
kinase 2 (CK2) (apigenin) and nuclear factor-B (NF-B) (NF-B activation inhibitor). RNA interference
assays showed signiﬁcant attenuation of the IL-1-induced expression of C/EBP following knockdown of
the p50 and p65 subunits of NF-B. IL-1 induced NF-B DNA binding and activation by this transcrip-
tion factor and this was attenuated by curcumin and apigenin. Taken together, these results suggest a
potentially crucial role for NF-B in the IL-1-induced expression of C/EBP, and thereby downstreamAPP
anscr
 genes regulated by this tr
. Introduction
The acute phase response (APR) is the body’s innate immune
efence against infection, inﬂammation, stress, physical trauma
nd pathological conditions such as cardiovascular disease (Ramji
t al., 1993a; Baumann and Gauldie, 1994). The APR is character-
zed by fever, leukocytosis, alteredmetabolism inmanyorgans, and
ramatic changes in the plasma concentrations of various acute
hase proteins (APP) (Ramji et al., 1993a; Baumann and Gauldie,
994). Numerous studies have suggested that such APP may act
s biomarkers and possibly causal agents in the development of
ardiovascular disease (Packard and Libby, 2008).
The APP can be distinguished into two major groups; the pos-
tive APP (e.g. hemopexin, C-reactive protein (CRP), ﬁbrinogen,
erum amyloid A (SAA)) whose plasma concentrations increase
uring the APR, and the negative APP (e.g. albumin, transferrin)
hose levels decrease (Ramji et al., 1993a; Baumann and Gauldie,
994). The main stimulators of APP production are inﬂammation-
ssociated cytokines such as interleukin-6 (IL-6), interleukin-1
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(IL-1), tumour necrosis factor- and interferon- (IFN-) (Ramji et
al., 1993a,b; BaumannandGauldie, 1994;Moshage, 1997). The liver
is the major site for APP production and cytokines regulate their
expressionmainly at the transcriptional level (Ramji et al., 1993a,b;
Baumann and Gauldie, 1994; Moshage, 1997). It is essential that
the molecular mechanisms underlying such regulation are fully
understood, particularly how cytokines modulate the action of key
transcription factors involved in this response. CCAAT/enhancer
bindingproteins (C/EBP) fall in this category (Ramji andFoka, 2002).
Transcription factors belonging to the C/EBP family contain a
conserved basic-leucine zipper motif at the carboxyl terminus that
is involved in dimerization and DNA binding (Ramji and Foka,
2002). There are six C/EBP family members (C/EBP to ), most of
which recognize similar DNA sequences, at least in vitro, and form
heterodimers in intrafamilial combinations (Ramji and Foka, 2002).
Binding sites for the C/EBPs have been identiﬁed in the regulatory
regions of a large number of APP genes, including hemopexin, hap-
toglobin, CRP, 1-acid glycoprotein, 2-macroglobulin, SAA-1, -2
and -3, complement C3, plasminogen and plasminogen activator
inhibitor-1 (Poli, 1998; Ramji and Foka, 2002; Bannach et al., 2004;
Open access under CC BY-NC-ND license.Dong et al., 2005, 2007). The general trend that has emerged from
these studies is that C/EBP homodimers or C/EBP:C/EBP het-
erodimers aremainly responsible for the constitutive transcription
(ChenandLiao, 1993;RayandRay,1994;Poli, 1998;Ramji andFoka,
2002). However, upon induction of the APR, C/EBP dimers are
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apidly replaced by C/EBP- and - homo-/heterodimers, although
he exact composition of these complexes varies with different
ene promoters and depends on the experimental models used
Ramji et al., 1993b; Chen and Liao, 1993; Ray and Ray, 1994; Poli,
998; Ramji and Foka, 2002).
The expression and the activity of C/EBP- and - are also stim-
lated by IL-1 and IL-6 (Ramji et al., 1993b; Poli, 1998; Ramji and
oka, 2002). Unfortunately, the molecular mechanisms underly-
ng such regulation are relatively poorly understood, particularly
hose relating to cytokine-induced expression, which are further
estricted to the action of IL-6 (Ramji and Foka, 2002). The pur-
ose of this study was therefore to investigate the mechanisms
nderlying the actions of IL-1 using C/EBP as a model gene.
. Materials and methods
.1. Reagents
The human hepatoma Hep3B cell line was from the Euro-
ean Collection of Animal Cell Cultures, whereas recombinant
L-1 (called IL-1 hereafter) was from Peprotech. Antibod-
es were from Cell Signalling Technology (p50/p105 NF-B;
65 NF-B; JNK; JNK pThr183/Tyr185; TAK1); Santa-Cruz
iotechnology [C/EBP (M17)X; c-Jun; CK2 and CK2′); or
igma (-actin). The non-radioactive JNK kinase assay kit
as from Cell Signalling Technology whereas small inter-
ering RNA (siRNA) were from either Qiagen [p50 NF-B
SI02654932);p65NF-B (SI02663094); TAK1 (SI02758756); JNK-1
SI02758673); JNK2 (SI02758637); andCK2′ (SI00605409)]; Invit-
ogen [CK2, 5′-ACCAGACGUUAACAGACUAUGAUAU-3′ (duplex
) and 5′-UCAUGAUUGAUCAUGAGCACAGAAA-3′ (duplex 2)]; or
mbion (Silencer® GAPDH siRNA control; NM 002046). The phar-
acological inhibitorswere fromAlexis Biochemicals (apigenin) or
erck (curcumin, NF-B activation inhibitor-NAI, SP600125).
.2. Cell culture
Hep3B cells were maintained in Dulbecco’s modiﬁed Eagle
edium (DMEM) with GlutaMAXTM containing 10% (v/v) heat-
nactivated fetal calf serum (HI-FCS) (30min at 56 ◦C), penicillin
100U/ml) and streptomycin (100g/ml) (designated as complete
edium). The cultures were maintained at 37 ◦C in a humid incu-
ator with a 5% (v/v) CO2 atmosphere. Treatment with IL-1 or
he different pharmacological agents was performed as previously
escribed (Mead et al., 2003; Harvey et al., 2007; Harris et al., 2008;
oka et al., 2009).
.3. RT-PCR
Total cellular RNA was isolated and subjected to RT-PCR
nd agarose gel electrophoresis essentially as described pre-
iously (Mead et al., 2003; Harvey et al., 2007; Foka et al.,
009) except that the total number of cycles and the anneal-
ng temperature varied: 25–29 cycles and 60 ◦C for C/EBP; 17
ycles and 60 ◦C for glyceraldehyde 3-phosphate dehydrogenase
GAPDH); and 10 cycles and 62 ◦C for 28SrRNA. The sequences
f the primers were 5′-GCGCGAGCGCAACAACATC-3′ and 5′-
CAGGTCCCGCGTGAGCT-3′ for C/EBP; 5′-CCCTTCATTGACCTCAA
TACATGG-3′ and 5′-AGTCTTCTGGGTGGCAGTGATGG-3′
or GAPDH; and 5′-TGAACTATGCTTGGGCAGGG-3′ and 5′-
GCGCCATCCATTTTCAGGG-3′ for 28SrRNA (Mead et al., 2003;
arvey et al., 2007; Foka et al., 2009). The PCR products were
ize-fractionated on a 2% (w/v) agarose gel, photographed using a
yngene gel documentation system (GRI) and quantiﬁed using the
ene Tools computer package (Syngene). The signals for C/EBP
ere normalized to the constitutive control (28SrRNA or GAPDH).mistry & Cell Biology 42 (2010) 113–119
2.4. Western blot analysis and c-Jun N-terminal kinase (JNK)
activity assays
Cellular extracts were prepared either as described previ-
ously (Mead et al., 2003; Harvey et al., 2007; Harris et al., 2008;
Foka et al., 2009) or using the Laemmli sample buffer [0.125M
Tris–HCl, pH 6.8; 4% (w/v) SDS; 10% (v/v) glycerol and 10% (v/v) 2-
mercaptoethanol). For the latter, the cells, grown in 9.5 cm2 dishes,
were washed with phosphate buffered saline, lysed using 75l
of Laemmli sample buffer, and the cellular proteins collected by
centrifugation. Western blot analysis was carried out as previously
described (Mead et al., 2003; Harvey et al., 2007; Harris et al., 2008;
Foka et al., 2009) whereas the JNK kinase activity assay on non-
denatured proteins was performed according to the instructions of
the manufacturers (Cell Signalling Technology). The signals from
thewestern blots were normalized to the constitutive-actin con-
trol.
2.5. Transient transfection assays
Transfection with plasmid DNA was carried out using
polyethylenimine (PEI) as previously described (Harvey et al.,
2007). The luciferase activity in cell extracts was determined using
a commercially available kit (Promega) andnormalized to total pro-
tein levels (determined using the microBCA protein assay kit from
Pierce).
2.6. siRNA-mediated knockdown
Transfection with siRNA was carried out using DharmaFECTTM
as recommended by themanufacturer (Dharmacon RNA Technolo-
gies). The cells were ﬁrst incubated with the transfected siRNA for
65h and, following aspiration of themedium, for the requisite time
in complete medium containing the vehicle or the cytokine.
2.7. Electrophoretic mobility shift assays (EMSA)
Whole cell and nuclear extracts were prepared and used
for EMSA as previously described (Mead et al., 2003; Harvey
et al., 2007; Harris et al., 2008; Foka et al., 2009). The
sequences of the oligonucleotides used were 5′-GGAGTTGAGGG
GACTTTCCCAGGC-3′ and 5′-GGCCTGGGAAAGTCCCCTCAACT-3′ for
NF-B and 5′-CGCTTGATGAGTCAG-3′ and 5′-TTCCGGCTGACTCAT-
3′ for AP-1. For antibody supershift/interference experiments, the
antibody (0.5g) was added to the binding reaction and incubated
on ice for 20min prior to the addition of the radiolabelled probe.
In competition assays, the binding reactionmixture was incubated
for 10min on ice with a 250-fold molar excess of unlabelled com-
petitor oligonucleotides prior to the addition of the radiolabelled
probe.
2.8. Statistical analysis
The intensity of bands from immunoblots and EMSAwere anal-
ysed using GeneToolsTM(Syngene). Statistical analyses of the data
was carried out using the Student’s t test with P<0.05 considered
as statistically signiﬁcant.
3. Results
3.1. IL-1 induces the expression of C/EBPı mRNA and protein in
Hep3B cells
The human hepatoma Hep3B cell line is used widely as a model
for liver-speciﬁc gene expression and cytokine-mediated regula-
tion of APP with demonstrated conservation to in vivo responses
S. Ali et al. / The International Journal of Biochem
Fig. 1. IL-1 increases the expression of C/EBP mRNA and protein. (A) Hep3B cells
were either left untreated or incubated with IL-1 (100U/ml) (− and +, respectively)
for the indicated period of time and total cellular RNAwas subjected to RT-PCRusing
primers for C/EBP or GAPDH. The ampliﬁcation products were size-fractionated by
agarose gel electrophoresis along with molecular size markers (M). −RT shows the
outcome of a reaction in which the reverse transcriptase step was omitted (RNA
from untreated cells at 0h was used) and NC indicates a reaction that contained
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on JNK activity in the absence or the presence of pharmacologi-ater instead of cDNA. (B) Western blot analysis was performed on extracts from
ells that were either left untreated (0h) or incubated with IL-1 (100U/ml) for the
ndicatedperiodof time, andantiserumagainst C/EBPor-actin. The results shown
n both panels A and B are representative of three independent experiments.
Hiron et al., 1992; Ramji et al., 1993a; Foka et al., 2009; Coulouarn
t al., 2004, 2005 and references therein). For example, the hep-
tocyte origin and pro-inﬂammatory cytokine responsiveness of
RNAs that were found to be upregulated in acute systemic
nﬂammation, as judged by complete coverage of the human liver
ranscriptome, has been conﬁrmed in these cells (Coulouarn et al.,
004). In addition, genome-wide studies in these cells in relation
o the actions of pro-inﬂammatory cytokines have shown proper
inetics of changes in mRNA abundances for cytokines and their
eceptors, transcription factors and APPs, with the overall per-
entage of regulated mRNAs (∼7%) being similar to the number
f liver mRNAs regulated during the APR in mouse or humans in
ivo (Coulouarn et al., 2005).
We have previously analysed the effect of IL-1 on C/EBP
xpression in J774.2 macrophages and glomerular mesangial cells
Tengku-Muhammad et al., 2000; Granger et al., 2000) but not in
ep3B cells. Thiswas therefore investigated by time course RT-PCR
ndwestern blot analysis. For RT-PCR, sequence analysis conﬁrmed
he speciﬁc ampliﬁcation of C/EBP. Fig. 1A shows that IL-1 induces
/EBPmRNAexpression that peaks at 3h and remains at similar or
lightly reduced levels throughout the 24h incubation period. Such
n inductionwasdue to IL-1 andnot becauseof anon-speciﬁc effect
f harvesting the cells at the various time-points. The expression of
he C/EBP protein was also induced by IL-1 at 3h post-treatment
nd was then expressed at reduced levels over the rest of the 24h
eriod (Fig. 1B). Statistical analysis of the data from three indepen-
ent experiments showed that the IL-1-induced expression of the
/EBP protein (normalized to -actin) was signiﬁcant (P<0.01 at
h, 6h and 12h and <0.05 at 24h). Overall, these data show that
L-1 induces C/EBPmRNA and protein expression in Hep3B cells,
hich is consistent with the previously noted activation of C/EBP
xpression in the liver during experimentally induced inﬂamma-
ion in rodents (Alam et al., 1992; Magalini et al., 1995). However,
he induced levels of C/EBP mRNA were maintained for a more
rolonged period than the corresponding protein. This suggests
hat, similar to the actions of several extracellular mediators on
he C/EBPs (Ramji and Foka, 2002; Magalini et al., 1995), multiple
echanisms are involved in the IL-1-mediated induction of C/EBP
xpression.
An IL-1-mediated induction of C/EBP promoter activity was
ot observed when transient transfection assays were carried out
sing luciferase-basedplasmids containing 1.6 kBof humanC/EBPistry & Cell Biology 42 (2010) 113–119 115
promoter (Sanford and DeWille, 2005) or 2.2 kB of mouse C/EBP
promoter (Hutt et al., 2000) (data not shown). As expected from
previous studies (Yamada et al., 1997; Cantwell et al., 1998; Sanford
and DeWille, 2005), both promoters were activated by IL-6 (data
not shown). IL-1 was functional in this system as it could acti-
vate the pNF-B-Luc plasmid (Clontech) which contains multiple
binding site of this transcription factor linked to a minimal pro-
moter upstream of the luciferase reporter gene (data not shown).
Although the precise reason(s) for the non-responsiveness of the
C/EBP promoter to IL-1 is currently unclear, it is possible that
either the regulatory sequences for IL-1 actions resideoutside those
present in the DNA constructs used or a speciﬁc chromatin context
is required for the response that is not present in the transfected
plasmids. Our further studies therefore focused on the signalling
pathways underlying IL-1 actions.
3.2. The IL-1-induced expression of C/EBPı is attenuated in the
presence of inhibitors of JNK, casein kinase 2 (CK2) and nuclear
factor- B (NF-B)
An initial screen analysing the effects of a single concentration
of pharmacological inhibitors against different signal transduc-
tion pathways showed that the IL-1-induced expression of C/EBP
mRNAwas signiﬁcantly attenuated by 30Mcurcumin and 20M
apigenin, inhibitors of JNK and CK2, respectively (Mead et al., 2003;
Li et al., 2005; Yamada et al., 2005; Singh and Ramji, 2006, 2008;
Parhar et al., 2007; Harris et al., 2008) (Fig. 2A). The action of these
two inhibitorswas therefore investigated inmore detail alongwith
SP600125, another JNK inhibitor (Han et al., 2001), and the NF-
B activation inhibitor (NAI) (Tobe et al., 2003) because of the
important role of this transcription factor in IL-1 signalling (Dunne
and O’Neill, 2003). All four inhibitors attenuated the IL-1-induced
expression of the C/EBP protein (Fig. 2B–E) (P<0.001 for cur-
cumin, 40M apigenin and 50M SP600125; <0.05 for 5M and
10MNAI; and<0.01 for 20Mapigenin and100MSP600125). A
similar attenuation by the inhibitorswas observed at the level of IL-
1-induced C/EBPmRNA expression (data not shown). Themarked
inhibition of the IL-1-mediated induction of C/EBP expression by
these pharmacological agents was not due to cellular toxicity as
judged by the speciﬁc inhibition of expression of C/EBP but not
28SrRNA or -actin (Fig. 2) and trypan blue exclusion assays using
different concentrations of all four inhibitors (data not shown).
3.3. IL-1 activates JNK in Hep3B cells
Differential splicing of the JNK genes leads to the generation of
two predominant forms of this enzyme, p54 and p46, and these can
be activated by phosphorylation at threonine 183 and tyrosine 185.
The action of IL-1 on the phosphorylation of JNKs at these two sites
was therefore investigated by western blot analysis. IL-1 increased
the levels of phosphorylated p54 without affecting the total levels
of the protein (Fig. 3A). Further experiments showed that such an
increase in JNK phosphorylation was due to IL-1 and not because
of incubation of the cells for the time period (Fig. I in supplemen-
tary data).
The activity of JNK can be monitored using an in vitro kinase
assay kit in which the ability of immunoprecipitated JNKs to phos-
phorylate c-Jun, its key downstream target, is determined. This
assay was therefore employed to determine the action of IL-1cal inhibitors. Consistent with the pattern of phospho-JNK levels
(Fig. 3A), IL-1 induced the activity of the enzyme (Fig. 3B) (P<0.05
at 15min and 30min). In addition, curcumin and SP600125, but
not apigenin, attenuated the IL-1-induced JNK activity (Fig. 3C)
(P<0.001 for both curcumin and SP600125).
1 iochemistry & Cell Biology 42 (2010) 113–119
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.4. siRNA-mediated knockdown of NF-B attenuates the
L-1-induced expression of C/EBPı
siRNA-mediatedknockdownof JNK-1and -2, the twoprominent
soforms expressed in hepatocytes, or its downstream target c-Jun
idnot attenuate the IL-1-inducedexpressionof theC/EBPprotein
Figs. IIA-IIB in supplementary data). Similarly, siRNA-mediated
nockdown of CK2- and -′, two of the three catalytic subunits of
his enzyme (Singh and Ramji, 2008) had no effect (Fig. IIC in sup-
lementary data). For JNK and CK2, the ﬁndings were conﬁrmed at
he level of C/EBP mRNA expression (data not shown). Although
heprecise reason(s) for these results are currentlyunclear, it ispos-
ible that this could be because of functional redundancy between
he different pathways and/or sufﬁcient amount of residual activ-
ty being present following siRNA-mediated knockdown. Because
t was not possible to simultaneously knockdown all the JNK and
K2 isoforms due to potential toxicity effects from the use of large
uantities of siRNA that would be required, the role of the down-
tream transcription factorNF-Bwas investigated. The expression
f both the p50 and p65 NF-B subunits, the two most abundant
soforms that play a key role in IL-1 signalling (Pereira and Oakley,
008),wasknockeddownby transfectionofHep3Bcellswith siRNA
gainst these two subunits but not GAPDH (Fig. 4A and B). The
ig. 2. The effect of pharmacological inhibitors on the IL-1-induced expression of
/EBP. (A) Hep3B cells were pre-treated for 1h with curcumin (Cur; 30M), api-
enin (Api; 20M) or DMSO as a vehicle control, or left for this period of time in
ormalmedium (Med). Theywere then incubated for 3h in the absence or the pres-
nceof IL-1 (100U/ml) (−and+, respectively) and total RNAwas subjected toRT-PCR
sing primers against C/EBP or 28SrRNA. The products were resolved by agarose
el electrophoresis along with molecular size markers (M). (B–E) The cells were
re-treated for 1h with DMSO or the indicated concentration of curcumin (Cur),
pigenin (Api), SP600125 (SP) or NAI (N), and then incubated for 3h in the absence
r the presence of IL-1 (− and +, respectively). Total cellular proteinswere subjected
o western blot analysis using antiserum against C/EBP or -actin. The data shown
re representative of three to four independent experiments (3 for SP600125 and
urcumin, and 4 for the others).
Fig. 3. IL-1 activates JNK activity in Hep3B cells. (A) The cells were treatedwith IL-1
(100U/ml) for the indicated period of time and whole cell extracts were subjected
to western blot analysis using antiserum against phospho- and total-JNK. (B and
C) The cells were treated in the absence or the presence of IL-1 (100U/ml) for the
indicated period of time (panel B), or pre-treated for 1h with the DMSO vehicle
control or the indicated concentrationof curcumin (Cur), SP600125or apigenin (Api)
and then incubated for 15min in the absence or the presence of this cytokine (− and
+, respectively) (panel C).Whole cell extractswere subjected to the JNK kinase assay
followed by western blot analysis with antiserum against phospho-c-Jun. Western
blots probed with the -actin antibody were used as a control for the amount of
proteins in the extracts. The results shown are representative of two (A) to three
(B–C) independent experiments.
IL-1-induced expression of the C/EBP protein was attenuated by
knockdown of p50 and p65 expression but not by GAPDH (Fig. 4A
and C). Knockdown had no effect on the expression of the -actin
protein (Fig. 4A). Similar results were obtained when the C/EBP
mRNA expression was monitored by RT-PCR (data not shown).
The IL-1-mediated activation of NF-B is known to occur via a
TAK-dependent or -independent manner (Yao et al., 2007). siRNA-
mediated knockdown of TAK1, however, failed to attenuate the IL-
1-induced expression of C/EBP (Fig. III in supplementary data),
thereby suggesting a potential TAK1-independent pathway.
3.5. The action of pharmacological inhibitors on the DNA binding
activity and the trans-activation potential of NF-B
Because the IL-1-induced expression of C/EBP was attenuated
by inhibitors of JNK and CK2 (Fig. 2), the action of these on NF-
B-mediated transcriptional activation along with its DNA binding
activity was investigated. Transfection assays using the pNF-B-
Luc plasmid, which contains multiple NF-B binding sites linked
to a luciferase reporter gene, showed that IL-1 induced its activ-
ity and this was attenuated in a statistically signiﬁcant manner by
both apigenin and curcumin (Fig. 5). The IL-1-mediated activation
of pNF-B-Luc was speciﬁc to this transcription factor because it
could be attenuated by expression of a superrepressor (IBN)
that inhibits NF-B action (Heissmeyer et al., 1999) (Fig. 5).
Time course EMSA using whole cell extracts and a radiolabelled
consensus NF-B binding site oligonucleotide as a probe (called
B oligonucleotide hereafter) showed the formation of at least ﬁve
DNA–protein complexes (labelled a–e in Fig. 6). From these, four
of the complexes (a, c, d and e) were present in untreated cells
(although signals for c and d were generally faint) and induced to
varying degrees by IL-1 treatment. On the other hand, complex b
was entirely inducedby IL-1 treatment. The induction ofNF-Bwas
S. Ali et al. / The International Journal of Biochemistry & Cell Biology 42 (2010) 113–119 117
Fig. 4. Effect of siRNA-mediated knockdown of p50 and p65 NF-B subunits on
the IL-1-induced expression of C/EBP. Hep3B cells were transfected with siRNA
against GAPDH or the p50 and p65 NF-B subunits together (the ﬁnal concentration
of siRNA was the same at 12.5nM). They were then either left untreated (−) or
incubated for 3h with 100U/ml IL-1 (+). Protein extracts were subjected to western
blot analysis with antiserum against p50 (also detects the p105 precursor), p65
and -actin as shown (panel A). Panel B shows the p50:-actin or the p65:-actin
ratios (mean± SD), as determined by densitometric scanning of signals from three
independent experiments, with the ratio fromGAPDH siRNA transfected cells being
arbitrarily assigned as 1. Panel C displays the C/EBP:-actin ratio with that from
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Fig. 5. The effect of apigenin and curcumin on NF-B-mediated trans-activation
in Hep3B cells. The cells were transfected with the pNF-B-Luc plasmid either
alone (experiments involving curcumin or apigenin where DMSO was used as a
vehicle control), or along with pcDNA3 control vector or the NF-B superrepres-
sor (IBN). The cells were then either left untreated or incubated for 3h with
100U/ml IL-1 (the inhibitors were added 1h before the addition of IL-1). The
luciferase activity in cell extracts was then determined and normalized to the total
mRNA and protein in Hep3B cells (Fig. 1) and this was attenu-
ated by inhibitors of JNK, CK2 and NF-B (Fig. 2). siRNA-mediated
knockdown of the p50 and p65 NF-B subunits attenuated the
IL-1 induced expression of C/EBP (Fig. 4). IL-1 stimulated NF-L-1 treated, GAPDH siRNA transfected cells being arbitrarily assigned as 1 with
he others represented to this value. Asterisks indicate signiﬁcant attenuation of
xpression following siRNA-mediated knockdown (***P<0.001).
ransient, being apparent 5min post-IL-1 treatment and decreased
t 180min. Further experiments focused on the 15min time point
here a marked IL-1 induced NF-B activity was observed.
A similar proﬁle of DNA–protein interactions was observed
ith both nuclear and whole cell extracts, thereby ruling out the
ossibility that the previously noted induction of NF-B activity
as peculiar to the use of whole cell extracts for EMSA (Fig. 7A).
he speciﬁcity of DNA–protein complexes was analysed by com-
etition EMSA and showed attenuation by pre-incubation of the
xtracts with a 250-foldmolar excess of the unlabelled B oligonu-
leotide but not by that containing the unrelated AP-1 binding site
Fig. 7B). The potential involvement of p50 and the p65 subunits,
he major components of NF-B in several modes of regulation
Pereira and Oakley, 2008), was investigated using antibody super-
hift/interference EMSA with non-immune serum serving as a
ontrol. Pre-incubation with the anti-p50 NF-B antibody resulted
n the formation of a slower migrating antibody-DNA-protein
upershift complex, complete inhibition of complex b, and partial
nhibition of complex a (Fig. 7B). On the other hand, pre-incubation
ith the anti-p65 antibody interfered with the formation of com-protein concentration. In each case, the normalized luciferase activity in untreated
cells was arbitrarily assigned as 1 (not shown) with those from IL-1 treated cells
represented as Fold induction. The results are mean± SD from three independent
experiments (*P<0.05; **P<0.01, ***P<0.001).
plexes a and d (Fig. 7B). These results suggest that, consistent with
the data for siRNA-mediated knockdown (Fig. 4), both p50 and
p65 were involved in DNA–protein interactions. Finally, the IL-1-
induced NF-B binding was attenuated by pre-treatment of the
cells with apigenin or curcumin. Densitometric analysis showed
that the inductionofNF-Bbindingby IL-1was signiﬁcant (P<0.05)
along with the attenuation of this by curcumin and apigenin
(P<0.01 and 0.05, respectively). Thus, similar to the previously
noted effect on trans-activation (Fig. 5), apigenin and curcumin also
attenuate the IL-1-induced NF-B DNA binding.
4. Discussion
Circulating levels of several APP are elevated during inﬂamma-
tion and inﬂammatory disorders such as cardiovascular disease
in response to increased transcription of these genes in hepato-
cytes by cytokines such as IL-1 (Ramji et al., 1993a,b; Baumann and
Gauldie, 1994; Moshage, 1997; Ramji and Foka, 2002; Packard and
Libby, 2008). Although the C/EBPs play crucial roles in such regula-
tion, the mechanisms underlying the actions of cytokines on these
transcription factors remain poorly understood (Ramji and Foka,
2002). We show here that IL-1 induces the expression of C/EBPFig. 6. Time course action of IL-1 on NF-B DNA binding. Hep3B cells were treated
with 100U/ml of IL-1 for the indicated period of time. Whole cell protein extracts
were used for EMSA with a radiolabelled B oligonucleotide probe. The different
DNA–protein complexes are labelled as a–e (the free probe has migrated off from
the gel). The results are representative of two independent experiments.
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Fig. 7. Analysis of DNA binding to NF-B binding site. EMSA was carried out using
either whole cell extracts (WCE in panel A and all samples in panels B and C) or
nuclear extracts (NE in panel A) fromHep3B cells that were either left untreated (−)
or incubatedwith 100U/ml of IL-1 for 15min (+ and all samples in panel B). Compe-
tition assays in panel B included either no competitor (none) or a 250-molar excess
of the B binding site oligonucleotide (NF-B) or that containing the AP-1 binding
site (AP-1). Panel B also shows the outcome of antibody interference assays using
non-immune serum (NIS) or antiserum against the p50 or p65 isoform of NF-B as
indicated. For panel C, curcumin (Cur; 50M) or apigenin (Api; 40M)were added
to the cells 1h before the addition of IL-1 and DMSO was used as a vehicle control.
The different DNA–protein complexes are labelled a–e (the free probe has migrated
off the gel). In panel B, ss p50 shows the antibody-DNA-protein supershift complex
produced by the p50 antibody, and the potential proteins involved in the forma-
t
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i
i
b
r
n
t
i
t
a
b
b
i
o
(
k
scription factor CCAAT/enhancer binding protein  (C/EBP). J Throb Haemostion of each complex, as judged from antibody interference assays, are indicated
n the right side (? indicates members other than p50 or p65). The data shown are
epresentative of two to three independent experiments.
B DNA binding and trans-activation, which was attenuated by
nhibitors of CK2 and JNK (Figs. 5–7). Although a role for JNK in IL-1-
nduced expression of C/EBP expression in hepatocytes, as judged
y inhibition of the response in HepG2 cells by SP600125, has been
eported (Dong et al., 2007), our studies also show important and
ovel roles for CK2 and NF-B.
The association of the JNK pathway in the control of inﬂamma-
ion is well established and recent studies have also suggested an
mportant role for CK2 (Singh and Ramji, 2008). In addition, these
wo pathways have also been implicated in IL-1 signalling (O’Neill
nd Greene, 1998; Singh and Ramji, 2008). For example, IL-1 has
een shown to activate CK2 in intestinal epithelial cells and inhi-
ition of this enzyme attenuates the expression of several genes
nduced by this cytokine (Parhar et al., 2007). Although inhibitors
f JNK and CK2 attenuated the IL-1-induced expression of C/EBP
Fig. 2), no such effect was observed following siRNA-mediated
nockdown of JNK-1/2 and CK2-/′ (e.g. Fig. II in supplemen-mistry & Cell Biology 42 (2010) 113–119
tary data). The precise reasons for these results are currently
unclear but could be due to functional redundancy between the
pathways. Indeed, such functional redundancy is relatively com-
mon in signalling cascades involved in the regulation of gene
expression as multiple pathways often regulate key transcription
factors such as NF-B (Mestre et al., 2001; Lowell et al., 1994).
In addition, as siRNA-mediated depletion of a target protein only
leads to a knockdown of expression, any remaining protein could
function to compensate for its reduced expression.
FiveNF-Bmembers exist inmammalian cells [RelA (p65), RelB,
c-Rel, p50/p105 (NF-B1) and p52/p100 (NF-B2) (May andGhosh,
1997; Pereira and Oakley, 2008). The p50 and p52 subunits are
produced by proteolytic processing of precursor proteins (p105
and p100, respectively) (May and Ghosh, 1997; Pereira and Oakley,
2008). Transcriptional regulation by this family is complex in part
due to extensive dimerization between the different proteins (May
and Ghosh, 1997; Pereira and Oakley, 2008). RelA (p65), RelB and
c-Rel contain a potent transcriptional activation domain at the car-
boxyl terminus (May and Ghosh, 1997). Although p50 and p52 lack
these domains, activation by p50 homodimers has been demon-
strated (May and Ghosh, 1997). Our studies show a crucial role for
p50 andp65 in the IL-1-inducedC/EBP expression. Both these sub-
unitswere involved inDNA–protein interactions, and IL-1 activated
NF-B DNA binding and trans-activation, which was attenuated
by curcumin and apigenin (Figs. 5–7). Whether the action of these
inhibitors onNF-B isdirect or a secondary response to inhibitionof
JNK and CK2 is currently unclear. However, cross-talk between JNK
and NF-B is relatively common (Wullaert et al., 2006). In addition,
IL-1 has been found to increase the association of CK2 and NF-B
(Bird et al., 1997; Singh and Ramji, 2008). Furthermore, CK2 has
been found to regulate the trans-activation potential of the p65
subunit along with other components of this pathway (Bird et al.,
1997; Parhar et al., 2007; Singh and Ramji, 2008). For example,
CK2-mediated phosphorylation of IB facilitates its degradation,
thereby leading to stimulation of transcription of NF-B gene tar-
gets (Singh and Ramji, 2008).
In conclusion, we show here for the ﬁrst time that NF-B plays
a crucial role in the IL-1 induced expression of C/EBP, a key tran-
scription factor in the activation of APP gene transcription. JNK and
CK2 were also involved in the response and modulated the IL-1-
induced trans-activation and DNA binding by NF-B. The studies
therefore provide novel insights into the molecular mechanisms
underlying the IL-1-mediated induction of APP gene transcription
in hepatocytes.
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